Regeneron and the associated logos are trademarks of Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals is a leading science-driven biotechnology company with a strong foundation in genetic discovery and biologics innovation. With decades of experience targeting inflammatory, metabolic, and fibrotic pathways, Regeneron is advancing new therapeutic strategies to address the rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).

Regeneron’s approach to MASH is rooted in its genetics-based drug discovery platform, enabling the identification of high-impact targets linked to liver fat accumulation, immune dysregulation, and fibrotic remodeling. Central to its pipeline is zalvegron (formerly known as REGNXXXXX) [placeholder name], a first-in-class biologic designed to inhibit key drivers of inflammation and fibrosis in the liver. In early-phase studies, Regeneron’s candidates have demonstrated the potential to improve liver histology, reduce biomarkers of inflammation, and halt progression toward cirrhosis.

In collaboration with its long-standing partner Alnylam Pharmaceuticals, Regeneron is also exploring RNA interference (RNAi) therapeutics targeting genetically validated pathways in lipid metabolism and hepatic fibrosis—opening new frontiers in durable, liver-targeted therapies for MASH and related cardiometabolic diseases.

Regeneron’s integrated model—combining genetic insights, large-scale data analytics, and cutting-edge biologic engineering—positions it to develop highly targeted and effective treatments for MASH. By focusing on disease modification and long-term risk reduction, the company aims to deliver precision therapies that meet the urgent unmet need in metabolic liver disease.